Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ADGI

ADGI - Adagio Therapeutics, Inc. Stock Price, Fair Value and News

4.02USD-0.09 (-2.19%)Delayed as of 21 Feb 2024, 01:01 pm ET
Watchlist

Market Summary

USD4.02-0.09
Delayedas of 21 Feb 2024, 01:01 pm
-2.19%

ADGI Stock Price

View Fullscreen

ADGI RSI Chart

ADGI Valuation

Market Cap

452.6M

Price/Earnings (Trailing)

-2.67

Price/Free Cashflow

-2.77

ADGI Price/Earnings (Trailing)

ADGI Profitability

Return on Equity

-68.79%

Return on Assets

-61.68%

Free Cashflow Yield

-36.05%

ADGI Fundamentals

ADGI Earnings

Earnings (TTM)

-169.6M

Earnings Growth (Yr)

12.52%

Earnings Growth (Qtr)

21.48%

Breaking Down ADGI Revenue

52 Week Range

4.09
(Low)(High)

Last 7 days

-15.7%

Last 30 days

-0.5%

Last 90 days

191.7%

How does ADGI drawdown profile look like?

ADGI Financial Health

Current Ratio

10.08

ADGI Investor Care

Shares Dilution (1Y)

1.04%

Diluted EPS (TTM)

-1.55

Tracking the Latest Insider Buys and Sells of Adagio Therapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Sep 01, 2022
hering david
bought
36,160
4.52
8,000
chief executive officer
Aug 19, 2022
elia marc
bought
2,700,160
4.62
584,451
-
Aug 18, 2022
elia marc
bought
5,454,520
4.31
1,265,550
-
Aug 17, 2022
elia marc
bought
4,040,000
4.04
1,000,000
-
Mar 03, 2022
adimab, llc
sold
-
-
-1,158,090
-
Aug 10, 2021
mcguire terrance
bought
8,500,000
17.00
500,000
-
Aug 10, 2021
mcguire terrance
acquired
-
-
8,031,700
-
Aug 10, 2021
redmile group, llc
bought
24,990,000
17.00
1,470,000
-
Aug 10, 2021
redmile group, llc
acquired
-
-
1,920,960
-
Aug 10, 2021
adimab, llc
acquired
-
-
25,860,700
-

1–10 of 15

Which funds bought or sold ADGI recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 15, 2024
BARCLAYS PLC
new
-
285,000
285,000
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
4.00
4.00
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
520
709,567
762,619
-%
Feb 14, 2024
BANK OF AMERICA CORP /DE/
added
1,336
170,123
175,393
-%
Feb 14, 2024
JACOBS LEVY EQUITY MANAGEMENT, INC
reduced
-14.41
698,958
1,409,480
0.01%
Feb 14, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
added
14.83
1,256,620
2,012,950
0.04%
Feb 14, 2024
GROUP ONE TRADING, L.P.
sold off
-100
-2,720
-
-%
Feb 14, 2024
MAVERICK CAPITAL LTD
added
77.29
27,855,700
36,815,200
0.74%
Feb 14, 2024
STATE STREET CORP
reduced
-0.51
391,046
690,513
-%
Feb 14, 2024
DEUTSCHE BANK AG\
sold off
-100
-5,029
-
-%

1–10 of 46

Are Funds Buying or Selling ADGI?

Are funds buying ADGI calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ADGI
No. of Funds

Unveiling Adagio Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
maverick capital ltd
8.5%
9,343,949
SC 13G
Feb 12, 2024
deep track capital, lp
7.56%
9e+06
SC 13G
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 22, 2024
adimab, llc
19.7%
21,687,906
SC 13D/A
Sep 11, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Aug 19, 2022
m28 capital management lp
8.50%
9,248,250
SC 13D/A
Jul 05, 2022
mithril ii lp
10.2%
11,241,580
SC 13D/A
Jun 24, 2022
population health equity partners iii, l.p.
33%
359,662
SC 13D/A
Jun 24, 2022
m28 capital management lp
5.78%
6,398,250
SC 13D/A

Recent SEC filings of Adagio Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 12, 2024
SC 13G
Major Ownership Report
Feb 09, 2024
8-K
Current Report
Feb 09, 2024
S-3
S-3
Feb 09, 2024
SC 13G/A
Major Ownership Report
Jan 26, 2024
3
Insider Trading
Jan 26, 2024
4
Insider Trading
Jan 22, 2024
4
Insider Trading
Jan 22, 2024
SC 13D/A
13D - Major Acquisition
Jan 19, 2024
144
Notice of Insider Sale Intent

Adagio Therapeutics, Inc. News

Latest updates
Seeking Alpha17 months ago
Investopedia2 years ago

Adagio Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets-12.8%275315351383425485556620686398258117
  Current Assets-12.9%270310345377422481554617680396-117
    Cash Equivalents49.1%18212212692.0027847553254247839391.00115
  Net PPE-5.7%2.002.002.002.001.000.000.000.00----
Liabilities-16.0%28.0034.0024.0027.0047.0070.0097.0062.0053.0038.0025.0013.00
  Current Liabilities-17.6%27.0033.0022.0025.0046.0068.0096.0062.0053.0038.00-13.00
Shareholder's Equity-12.5%2462823273563774154595586334.001.000.00
  Retained Earnings-6.4%-658-618-568-533-488-443-392-292-209-148--65.32
  Additional Paid-In Capital0.5%9059018968908668598528508424.00-0.00
Shares Outstanding0.3%11011010910910810810811161.006.00-6.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q3
Cashflow From Operations5.5%-35,352-37,391-41,181-47,404-56,142-57,392-59,049-73,212-54,213-33,570-23,741-13,428-1,143
  Share Based Compensation-8.8%4,2644,6775,4005,9057,3996,3611,9837,8565,9793,3425871487.00
Cashflow From Investing191.9%95,13532,59575,036-138,813-140,837-17.0049,000137,916-188,627----
Cashflow From Financing-65.9%92.0027054214124674.0045.00-749328,600334,832-79,83949,720
  Buy Backs-100.0%-1.00---2.002.00-----82.0085.00

ADGI Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:    
Research and development[1]$ 25,574$ 30,131$ 96,393$ 159,295
Acquired in-process research and development[2]4,6004,0005,5754,000
Selling, general and administrative12,88613,20034,03836,524
Total operating expenses43,06047,331136,006199,819
Loss from operations(43,060)(47,331)(136,006)(199,819)
Other income (expense):    
Other income3,6202,24411,0173,076
Total other income3,6202,24411,0173,076
Net loss(39,440)(45,087)(124,989)(196,743)
Other comprehensive income (loss)    
Unrealized gain on available-for-sale securities, net of tax204627054
Comprehensive loss$ (39,420)$ (45,041)$ (124,719)$ (196,689)
Earnings Per Share, Basic$ (0.36)$ (0.42)$ (1.14)$ (1.82)
Earnings Per Share, Diluted$ (0.36)$ (0.42)$ (1.14)$ (1.82)
Weighted Average Number of Shares Outstanding, Basic109,754,812108,420,674109,333,684108,154,397
Weighted Average Number of Shares Outstanding, Diluted109,754,812108,420,674109,333,684108,154,397
[1]Includes related-party amounts of $1,448 and $6,666 for the three and nine months ended September 30, 2023, respectively, and $1,742 and $6,027 for the three and nine months ended September 30, 2022, respectively
[2]Includes related-party amounts of $4,600 and $4,975 for the three and nine months ended September 30, 2023, respectively, and $4,000 for both the three and nine months ended September 30, 2022 (see Note 15).

ADGI Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 181,822$ 92,076
Marketable securities83,063279,915
Prepaid expenses and other current assets5,2184,926
Total current assets270,103376,917
Property and equipment, net2,0022,282
Operating lease right-of-use asset2,6253,777
Other non-current assets187191
Total assets274,917383,167
Current liabilities:  
Accounts payable9,1681,517
Accrued expenses15,95821,911
Operating lease liability, current1,6381,559
Other current liabilities2744
Total current liabilities26,79125,031
Operating lease liability, non-current9272,165
Other non-current liability7000
Early-exercise liability01
Total liabilities28,41827,197
Commitments and contingencies (Note 9)
Stockholders' equity (deficit):  
Preferred stock (undesignated), $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding at September 30, 2023 and December 31, 202200
Common stock, $0.0001 par value; 1,000,000,000 shares authorized, 109,846,329 shares issued and outstanding at September 30, 2023; 109,044,046 shares issued and outstanding at December 31, 20221111
Additional paid-in capital904,905889,657
Accumulated other comprehensive loss(2)(272)
Accumulated deficit(658,415)(533,426)
Total stockholders' equity246,499355,970
Total liabilities, preferred stock and stockholders' equity$ 274,917$ 383,167
ADGI
0
 WEBSITEadagiotx.com

Adagio Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for Adagio Therapeutics, Inc.? What does ADGI stand for in stocks?

ADGI is the stock ticker symbol of Adagio Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Adagio Therapeutics, Inc. (ADGI)?

As of Tue Feb 20 2024, market cap of Adagio Therapeutics, Inc. is 452.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADGI stock?

You can check ADGI's fair value in chart for subscribers.

What is the fair value of ADGI stock?

You can check ADGI's fair value in chart for subscribers. The fair value of Adagio Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Adagio Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADGI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Adagio Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether ADGI is over valued or under valued. Whether Adagio Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Adagio Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADGI.